Storys zum Thema Medikament

Europäischer Rechnungshof - European Court of Auditors

(Presskonferens) Kan EU bota bristen på kritiska läkemedel?

Kan EU bota bristen på kritiska läkemedel? - Presskonferens online onsdagen den 17 september kl. 10.00 CEST. - Offentliggörande samma dag kl. 17.00 CEST. Europeiska revisionsrätten inbjuder härmed till en presskonferens online inför offentliggörandet av en särskild rapport om EU:s åtgärder för att säkerställa ...

Europäischer Rechnungshof - European Court of Auditors

(Ενημέρωση Τύπου) Μπορεί η ΕΕ να θεραπεύσει τις ελλείψεις σε φάρμακα κρίσιμης σημασίας;

Μπορεί η ΕΕ να θεραπεύσει τις ελλείψεις σε φάρμακα κρίσιμης σημασίας; - Διαδικτυακή ενημέρωση Τύπου: Τετάρτη 17 Σεπτεμβρίου, ...

Europäischer Rechnungshof - European Court of Auditors

(Tiedotustilaisuus) Voiko EU löytää parannuskeinon lääkepulaan?

Voiko EU löytää parannuskeinon lääkepulaan? - Tiedotustilaisuus verkossa keskiviikkona 17. syyskuuta klo 10.00 Keski-Euroopan kesäaikaa - Kertomus julkaistaan samana päivänä klo 17.00 Keski-Euroopan kesäaikaa Euroopan tilintarkastustuomioistuin kutsuu teidät ...

Europäischer Rechnungshof - European Court of Auditors

(Pressebriefing) Kan EU afhjælpe kritiske mangler på lægemidler?

Kan EU afhjælpe kritiske mangler på lægemidler? - Online pressebriefing: onsdag den 17. september kl. 10.00 CEST - Offentliggørelse: samme dag kl. 17.00 CEST Den Europæiske Revisionsret inviterer til online pressebriefing vedrørende sin kommende særberetning om EU's foranstaltninger til at sikre tilgængelighed af lægemidler ...

Europäischer Rechnungshof - European Court of Auditors

(Press briefing) Can the EU cure critical medicine shortages?

Can the EU cure critical medicine shortages? - Online press briefing: Wednesday 17 September at 10.00 a.m. CEST - Publication: Same day at 5.00 p.m. CEST The European Court of Auditors (ECA) would like to invite you to an online press briefing on its upcoming special report on EU measures to ensure the availability of medicines – ...

Europäischer Rechnungshof - European Court of Auditors

(Spotkanie informacyjne) Czy UE rozwiąże problem krytycznych niedoborów leków?

Czy UE rozwiąże problem krytycznych niedoborów leków? - Spotkanie informacyjne online – środa 17 września o godz. 10.00 CEST - Publikacja – tego samego dnia o godz. 17.00 Europejski Trybunał Obrachunkowy serdecznie zaprasza na spotkanie informacyjne online dla prasy ...

DHL Group

PM: DHL übernimmt SDS Rx und stärkt damit seine Kompetenzen im Bereich Life Sciences und Healthcare / PR: DHL Agrees to Acquire SDS Rx Expanding Its Life Sciences and Healthcare Capabilities

Asklepios Kliniken GmbH & Co. KGaA

Nominations for the Broermann Medical Innovation Award 2026 now open

Hamburg (ots) - - With a million euros, it is one of the world’s most highly endowed awards for medical research The nomination period for the Broermann Medical Innovation Award 2026 has begun. Endowed with a million euros, this international award is among the most prestigious honors for medical research worldwide. Scientists from around the globe who have made ...

Grünenthal Group

Grünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors

Aachen (ots) - Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery ...

D4L data4life gGmbH

Data4Life announces the appointment of Dr. Ben Illigens as new CEO by the Hasso Plattner Foundation

UCB

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Brussels (ots/PRNewswire) - - 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning ...

STADA Arzneimittel AG

Press release: Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...

Helmholtz Munich

2

New Endoscopy Technology Enables Early Detection of Esophageal Cancer

Technische Universität München

A new biotech hub for Munich

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE A new biotech hub for Munich Where science powers start-ups: Launching BioLabs|TUM • TUM Venture Labs cooperate with BioLabs and Lilly • 1,800 square meters of coworking lab space • Aiming at accelerating therapy development BioLabs, TUM Venture Labs, and Eli Lilly and Company (Lilly) today launched BioLabs|TUM, a new biotechnology innovation hub in central Munich. The initiative aims to empower early-stage biotech start-ups ...

Helmholtz Munich

Therapeutic Vaccine for Chronic Hepatitis B Enters First Clinical Trial in Patients

CROMA-PHARMA GmbH

Croma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast

Leobendorf, Austria (ots/PRNewswire) - Saypha® injectables to launch in the U.S. under the Obagi Medical brand, expanding global reach of Croma's science-driven aesthetic solutions Croma-Pharma GmbH, a global leader in minimally invasive aesthetic medicine, today announced the acquisition of Novaestiq Corp. by Waldencast plc (Nasdaq: WALD). Novaestiq, a joint venture ...

Syntellix AG

Singapore-Based Innovative Biomedical Start-Up Achieves “Strategic Triumph“ to Conquer Chinese Med-Tech Market

Hanover/Beijing/Singapore (ots) - ● NMPA grants Syntellix product approval for the world's most important future market with more than 1.4 billion people ● Syntellix‘ product approval for China is the largest and most important success in the company’s history; product approval in China was the company’s ...

Helmholtz Munich

Cancer Cachexia: Liver Identified as Driver of Body Wasting

Many people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected, which further weakens the body. This wasting syndrome, known as cachexia, affects around half of all cancer patients. It is a major cause of therapy resistance, complications, and increased mortality. ...

Helmholtz Munich

2

New Label-Free Imaging Tracks Cancer Treatment in Single Cells

Ichnos Glenmark Innovation

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

New York and North Chicago, Ill. (ots/PRNewswire) - - ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an ...

Fraunhofer-Institut für Produktionstechnologie IPT

Transforming personalized medicine with AI-driven CAR-T manufacturing: Automated CAR-T cell production platform is ready for production

LTS Lohmann Therapie-Systeme AG

LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success

Andernach / Montreal (ots) - LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today announced a strategic collaboration to provide customers with robust, reliable, high-quality ...

Hagleitner Hygiene International GmbH

Global Hygiene Expert Pittet: Hand Hygiene Saves 5 to 8 Million Lives Each Year

Isomorphic Labs

Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence

London and Boston (ots/PRNewswire) - Precision oncology leader joins world-class team as company enters next phase of translating AI-driven drug discovery into life-changing medicines. Isomorphic Labs, the AI-first drug discovery company, has announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief Medical Officer. Dr. Wolf will be based in the company's newly ...